Evaluation of the Immunogenicity of an Experimental Subunit Vaccine That Allows Differentiation between Infected and Vaccinated Animals against Bluetongue Virus Serotype 8 in Cattle
Open Access
- 1 August 2013
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 20 (8) , 1115-1122
Abstract
Bluetongue virus (BTV), the causative agent of bluetongue in ruminants, is an emerging virus in northern Europe. The 2006 outbreak of BTV serotype 8 (BTV-8) in Europe was marked by an unusual teratogenic effect and a high frequency of clinical signs in cattle. Conventional control strategies targeting small ruminants were therefore extended to include cattle. Since cattle were not routinely vaccinated before 2006, the immune responses to BTV have not been studied extensively in this species. With the aims of developing a subunit vaccine against BTV-8 for differentiation between infected and vaccinated animals based on viral protein 7 (VP7) antibody detection and of improving the current understanding of the immunogenicity of BTV proteins in cattle, the immune responses induced by recombinant VP2 (BTV-8) and nonstructural protein 1 (NS1) and NS2 (BTV-2) were studied. Cows were immunized twice (with a 3-week interval) with the experimental vaccine, a commercial inactivated vaccine, or a placebo. The two vaccines induced similar neutralizing antibody responses to BTV-8. Furthermore, the antibody responses detected against VP2, NS1, and NS2 were strongest in the animals immunized with the experimental vaccine, and for the first time, a serotype cross-reactive antibody response to NS2 was shown in cattle vaccinated with the commercial vaccine. The two vaccines evoked measurable T cell responses against NS1, thereby supporting a bovine cross-reactive T cell response. Finally, VP7 seroconversion was observed after vaccination with the commercial vaccine, as in natural infections, but not after vaccination with the experimental vaccine, indicating that the experimental vaccine may allow the differentiation of vaccinated animals from infected animals regardless of BTV serotype. The experimental vaccine will be further evaluated during a virulent challenge in a high-containment facility.Keywords
This publication has 55 references indexed in Scilit:
- Control of bluetongue in EuropeVeterinary Microbiology, 2013
- Protection of IFNAR (−/−) Mice against Bluetongue Virus Serotype 8, by Heterologous (DNA/rMVA) and Homologous (rMVA/rMVA) Vaccination, Expressing Outer-Capsid Protein VP2PLOS ONE, 2013
- Multiserotype Protection Elicited by a Combinatorial Prime-Boost Vaccination Strategy against Bluetongue VirusPLOS ONE, 2012
- Characterization of the Immune Response Induced by a Commercially Available Inactivated Bluetongue Virus Serotype 1 Vaccine in SheepThe Scientific World Journal, 2012
- Identification and Characterization of a Novel Non-Structural Protein of Bluetongue VirusPLOS Pathogens, 2011
- Complete Genome Characterisation of a Novel 26th Bluetongue Virus Serotype from KuwaitPLOS ONE, 2011
- Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goatsVaccine, 2011
- Insights into the role of the non-structural protein 2 (NS2) in Bluetongue virus morphogenesisVirus Research, 2010
- Immunomodulation by Iscoms, Immune Stimulating ComplexesMethods, 1999
- Antigen specificity of the ovine cytotoxic T lymphocyte response to bluetongue virusVeterinary Immunology and Immunopathology, 1995